Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27736234 | 0.79 | APP (0.41) | DAOERCC5FEN1ARAPP | |
| SCHEMBL4086919 | 0.75 | DAO (0.52) | ALDH1A1DAOERCC5FEN1S1PR1 | |
| SCHEMBL27879696 | 0.67 | CTNNB1 (0.37) | ALDH1A1DAOERCC5FEN1S1PR1 | |
| SCHEMBL22458451 | 0.64 | CYP2C19 (0.47) | ALDH1A1CYP2C19HIF1AAPP | |
| SCHEMBL16345886 | 0.64 | DAO (0.39) | ALDH1A1DAOERCC5FEN1 | |
| SCHEMBL12153753 | 0.62 | DAO (0.44) | ALDH1A1DAORXFP1ERCC5FEN1 | |
| SCHEMBL22020943 | 0.61 | PTGS2 (0.33) | — | |
| SCHEMBL5331438 | 0.61 | CES2 (0.39) | ALDH1A1DAORXFP1CYP2C19HIF1A | |
| SCHEMBL17283102 | 0.60 | HIF1A (0.40) | CYP2C19HIF1ATBXA2R | |
| SCHEMBL1971165 | 0.60 | TSHR (0.41) | ALDH1A1DAOCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102762534-A | Aryl sulfone derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD | 2012-10-31 | — | — | CN | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | ALDH1A1 389/4885DAO 1109/4885RXFP1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.